drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (autologous T cells)
drug_description
Autologous adoptive T-cell therapy consisting of ex vivo expanded, tumor‑reactive T lymphocytes harvested from tumor‑draining lymph nodes; administered after lymphodepletion to mediate antigen-specific cytotoxicity.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Adoptive Immunotherapy
drug_category
TCR SELECTED T CELLS
drug_class
Unedited cells
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous tumor‑reactive T lymphocytes harvested from tumor‑draining lymph nodes are expanded ex vivo and reinfused after lymphodepletion. These unengineered T cells recognize tumor antigens via their native TCRs in an MHC‑restricted manner, expand (with IL‑2 support), and mediate antigen‑specific cytotoxicity through perforin/granzyme release and cytokine production to eliminate tumor cells.
drug_name
Autologous tumor-draining lymph node–derived lymphocytes (LNLs)
nct_id_drug_ref
NCT05981014